These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice. Eslam M; George J J Hepatol; 2020 Nov; 73(5):1268-1269. PubMed ID: 32800588 [No Abstract] [Full Text] [Related]
6. Response to: Comparison of MAFLD and NAFLD diagnostic criteria in real world. Nguyen VH; Le MH; Henry L; Cheung R Liver Int; 2020 Dec; 40(12):3145. PubMed ID: 32941668 [No Abstract] [Full Text] [Related]
7. Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data. Targher G Liver Int; 2020 Nov; 40(11):2879-2880. PubMed ID: 32738082 [No Abstract] [Full Text] [Related]
8. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Mendez-Sanchez N; Arrese M; Gadano A; Oliveira CP; Fassio E; Arab JP; Chávez-Tapia NC; Dirchwolf M; Torre A; Ridruejo E; Pinchemel-Cotrim H; Castellanos Fernández MI; Uribe M; Girala M; Diaz-Ferrer J; Restrepo JC; Padilla-Machaca M; Dagher L; Gatica M; Olaechea B; Pessôa MG; Silva M Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):65-72. PubMed ID: 33181118 [TBL] [Abstract][Full Text] [Related]
9. Sarcopenia and fatty liver disease. Kim JA; Choi KM Hepatol Int; 2019 Nov; 13(6):674-687. PubMed ID: 31705444 [TBL] [Abstract][Full Text] [Related]
10. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Shiha G; Alswat K; Al Khatry M; Sharara AI; Örmeci N; Waked I; Benazzouz M; Al-Ali F; Hamed AE; Hamoudi W; Attia D; Derbala M; Sharaf-Eldin M; Al-Busafi SA; Zaky S; Bamakhrama K; Ibrahim N; Ajlouni Y; Sabbah M; Salama M; Anushiravani A; Afredj N; Barakat S; Hashim A; Fouad Y; Soliman R Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):57-64. PubMed ID: 33181119 [TBL] [Abstract][Full Text] [Related]
11. Authors' response to 'Concordance of MAFLD and NAFLD diagnostic criteria in "real-world" data'. Huang J; Kumar R; Zhu Y; Lin S Liver Int; 2020 Nov; 40(11):2880-2881. PubMed ID: 32889767 [No Abstract] [Full Text] [Related]
12. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models. Zhao QY; Ge LH; Zhang K; Chen HF; Zhan XX; Yang Y; Dang QL; Zheng Y; Zhou HB; Lyu JX; Fang HZ Zool Res; 2020 Sep; 41(5):539-551. PubMed ID: 32786176 [TBL] [Abstract][Full Text] [Related]
13. Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. Alem SA; Gaber Y; Abdalla M; Said E; Fouad Y J Hepatol; 2021 May; 74(5):1261-1262. PubMed ID: 33497764 [No Abstract] [Full Text] [Related]
14. Re: Fouad Y, et al. The NAFLD-MAFLD debate: Eminence versus evidence. Liver Int. 2020 Nov 21. doi: 10.1111/liv.14739. Sierra F; Cárdenas A Liver Int; 2021 May; 41(5):1162-1163. PubMed ID: 33280222 [No Abstract] [Full Text] [Related]
16. [NASH: new terminology and what else is new in 2020]. Spahr L; Giostra E; Negro F; Goossens N Rev Med Suisse; 2020 Sep; 16(704):1544-1547. PubMed ID: 32880109 [TBL] [Abstract][Full Text] [Related]
17. Redefining fatty liver disease: an international patient perspective. Shiha G; Korenjak M; Eskridge W; Casanovas T; Velez-Moller P; Högström S; Richardson B; Munoz C; Sigurðardóttir S; Coulibaly A; Milan M; Bautista F; Leung NWY; Mooney V; Obekpa S; Bech E; Polavarapu N; Hamed AE; Radiani T; Purwanto E; Bright B; Ali M; Dovia CK; McColaugh L; Koulla Y; Dufour JF; Soliman R; Eslam M Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):73-79. PubMed ID: 33031758 [TBL] [Abstract][Full Text] [Related]
18. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues. Mushtaq K; Khan MU; Iqbal F; Alsoub DH; Chaudhry HS; Ata F; Iqbal P; Elfert K; Balaraju G; Almaslamani M; Al-Ejji K; AlKaabi S; Kamel YM J Hepatol; 2021 Feb; 74(2):482-484. PubMed ID: 33223215 [No Abstract] [Full Text] [Related]
19. [Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016]. Chen YS; Wang BY; Li YM Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):181-186. PubMed ID: 28482404 [TBL] [Abstract][Full Text] [Related]
20. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD). Johnston MP; Patel J; Byrne CD Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]